Colorectal Cancer The
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
2010 Commonwealth Games ~ 2010 Nobel Prizes ~ Sachin Tendulkar ~ Rajasthan Royals ~ Kings XI Punjab ~ Sushil Kumar ~ Deepika Kumari ~ Somdev Devvarman ~ HR Bhardwaj
Home / India News / 2007 / February / February 16, 2007
Colorectal Cancer: The Third Leading Cancer Type in the United States

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

Manmohan Singh to campaign in Bihar today

FBI failed to act on Headley's wife's terror link expose 3 yrs before Mumbai attacks

Craven's horror flicks 'were inspired by real stories'

RBI will intervene if inflows turn lumpy: Subbarao

Enforcement Directorate issues 'Look Out Circular' against Lalit Modi

Now, laser technology that destroys tumours using heat

Waist size, not BMI can foretell cardiovascular risk in children

Colorectal Cancer: The Third Leading Cancer Type in the United States

Mumbai, Maharashtra, India

According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer among both men and women in the United States, accounting for approximately 55,000 deaths every year. Treatment is complex, with new product advances in both cytotoxic and targeted therapy drugs changing the landscape of options and pathways utilized by physicians to fight the disease.

New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Colorectal Cancer Markets: Patient Outlook, provides an overview and patient population analysis for colon and rectal cancer in the United States from 2003-2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Colorectal Cancer Markets: Patient Outlook, then send an e-mail to Shwetha Thomas - Corporate Communications at sthomas@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

Proper understanding of the potential scope of various colorectal patient groups, divided according to factors such as disease progression and line of therapy, is important to judge the appropriate market size available for oncology products targeting colorectal cancer.

"Although the incidence of colorectal cancer is declining, it is not sufficient to offset aging population factors that are resulting in a year-over-year increase in the number of patient cases," explains Frost & Sullivan Industry Manager Daniel Ruppar. "Having an understanding of population factors and size is important in judging market opportunities, both for existing product expansion and new product development."

Among therapies, the percentage of patients receiving chemotherapy is increasing for both rectal and colon cancer. This trend, combined with an aging patient population, expects to contribute to growth in the use of adjuvant therapy.

With respect to stage IV cancer patients, projection through 2013 shows an increasing percent of patients willing to accept treatment through pharmaceuticals. Going by the base year trends, approximately 74 percent of stage IV rectal cancer patients and 53 percent of stage IV colon cancer patients are estimated to take pharmaceuticals as part of their treatment in 2013. New drug treatments expect to expand the therapeutic opportunities for patients, especially for those with late stage disease progression.

Patient survival is a crucial factor for drugs utilized in the treatment of colorectal cancer. Proven clinical outcomes, in regards to survival, expect to continue to be important for new products awaiting Food and Drug Administration (FDA) approval, or existing products looking to expand indications.

"New treatments for colorectal cancer are improving the survival time of patients with the disease, "says Ruppar. "Determining the optimal treatment for each patient is important, with an indicative line of therapy having a direct impact on the revenue potential for products in this space."

While recent advances in targeted therapies and improvements in chemotherapy are improving the lives of patients with colorectal cancer, continued innovation and product development is needed, especially since the colorectal cancer is the third leading disease in terms of patients for the oncology area.

U.S. Colorectal Cancer Markets: Patient Outlook is part of the Pharmaceuticals and Biotechnology Subscription, which also includes research in the following markets: U.S. intranasal drug delivery market, U.S. antiplatelet market, and emerging therapeutics in the U.S. colorectal cancer markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership service, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

U.S. Colorectal Cancer Markets: Patient Outlook
N0DE-52

Shwetha Thomas, Corporate Communications - South Asia, Middle East, Frost & Sullivan, +91 (022) 4001 3429 sthomas@frost.com

Melina Trevino, Corporate Communications - North America, Frost & Sullivan, +1 210 247 2440 melina.trevino@frost.com

Source: Frost & Sullivan (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.

India News / Press Releases on February 16, 2007

The Writers Block Strengthens the Technical Writing Value Chain in India
Business Wire India

New Styling Options and Product Categories will Stimulate Interest in Exterior Protection Accessories
Business Wire India

Peer-to-Peer Technologies Hold the Key to Tapping the Next Generation Needs of Small Enterprises
Business Wire India

Colorectal Cancer: The Third Leading Cancer Type in the United States
Business Wire India

Also see International News / Press Releases on February 16, 2007

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us